United Therapeutics Corporation (NASDAQ:UTHR) released its second-quarter financial results on Wednesday, revealing earnings that missed Wall Street expectations, even as the company delivered record revenue for the period.
The biotech firm reported adjusted earnings of $6.41 per share, falling $0.94 below the analyst forecast of $7.35. Revenue reached $798.6 million, just shy of the anticipated $804.98 million.
Compared to the same quarter a year ago, revenue increased by 12% from $714.9 million, continuing a notable streak of double-digit revenue growth for the 12th quarter in a row.
Following the announcement, shares of United Therapeutics saw little movement, ticking up a marginal 0.01% in premarket trading.
One of the key highlights was Tyvaso DPI, which set a new high-water mark with $315 million in quarterly revenue—a 22% jump over the previous three-month period.
Additionally, the company recorded strong year-over-year revenue gains for several products, including Nebulized Tyvaso, Orenitram, and Unituxin. Notably, Orenitram achieved its highest quarterly revenue to date.
“Our second quarter yet again produced record-setting results driven by the strength of our foundational commercial business,” said Martine Rothblatt, Chairperson and CEO of United Therapeutics. “We continue to believe there is no other biotech company like ours that provides this combination of sales growth and operating cash flow with near- to medium-term catalysts positioned for sustained long-term growth.”
Reinforcing its financial strength, the company’s Board of Directors approved a share buyback program of up to $1 billion, set to run through March 31, 2026.
On the R&D front, United Therapeutics reported progress in its clinical pipeline, with the Phase 3 TETON 2 trial evaluating Nebulized Tyvaso in idiopathic pulmonary fibrosis now completed. Results from the study are expected in September 2025.
United Therapeutics Corporation stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.